Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Anti-Virulence, and Antioxidant Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PON2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PON2 Recombinant Protein / Catalytic Domain High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PON2 Products |
| Gene Delivery | PON2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PON2 Products |
| Benchmark Ab | Anti-PON2 Recombinant Antibody Sequence Verified positive control for Western Blot and IHC. |
View PON2 Products |
| Validator | PON2 siRNA Set For knockdown verification and phenotypic sensitization assays. |
View PON2 Products |
| Related Target A | PON1 Homolog counter-screening to ensure selective PON2 modulation without impacting circulating serum esterase activity. |
View PON1 Products |
| Related Target B | PON3 Related mitochondrial and endoplasmic reticulum lactonase family member for selectivity profiling. |
View PON3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter-Screening (PON1/PON3 selectivity) | Homolog panel proteins (PON1, PON2, PON3) strictly sequence-verified and expressed with high purity (>95%) for enzymatic selectivity profiling. |
| Intracellular & Membrane-Associated Localization | Full-length PON2 Lentivirus particles for constructing stable overexpressing cell lines to preserve native ER/mitochondrial membrane anchoring. |
| Lack of Robust Controls | Sequence-verified recombinant positive control antibodies and recombinant lactonase catalytic domains included. |
| False Positives in Phenotypic Screening | Validated siRNA sets included for rigorous specificity checks and knockdown verification in chemo-sensitization assays. |
Live PON2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PON2 therapeutics is intensifying across two major therapeutic frontiers: oncology drug resistance and bacterial quorum sensing inhibition. Unlike PON1 and PON3, PON2 is localized intracellularly—primarily to the endoplasmic reticulum and inner mitochondrial membrane—where it functions as a potent antioxidant and lactonase. In oncology, major research initiatives are focusing on PON2 as a master regulator of chemo-resistance and apoptosis evasion in refractory solid tumors, including pancreatic ductal adenocarcinoma, glioblastoma, and hematologic malignancies. Meanwhile, its unique capacity to hydrolyze acyl-homoserine lactones (AHLs) positions engineered PON2 biotherapeutics as promising anti-virulence strategies against Pseudomonas aeruginosa biofilm formation and cystic fibrosis lung infections. As first-generation small molecule inhibitors and enzyme-based therapies progress, the next wave of R&D is targeting selective intracellular lactonase modulation without disrupting systemic cardioprotective pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic & Biotech Consortia | Refractory Solid Tumors, Leukemia (Chemo/TKI Sensitization) | Enzymatic Selectivity Assay (Need High-purity PON2 vs. PON1/PON3 Proteins) |
| Engineered Biotherapeutic / Enzyme Therapy | Anti-Infective Biotechs | P. aeruginosa Infection, Cystic Fibrosis Biofilms | Lactonase Activity & AHL Hydrolysis Validation (Need Sequence Verified PON2 Catalytic Domain) |
| Gene Therapy / mRNA | Cardiovascular & Rare Disease Developers | Atherosclerosis, Ischemia-Reperfusion Injury | Intracellular Functional Validation (Need Stable Lentivirus Cell Lines) |